Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3095 in Healthy Subjects
NCT07230418Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing HRS-3095 Group with HRS-3095 Placebo Group (2 arms). Primary endpoints: Incidence of adverse events at 21 days and Incidence of serious adverse events at 21 days. Started Nov 2025; status: completed.
02
Drugs
HRS-3095
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07230418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230418.